Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Anika Therapeutics (ANIK) EBITDA (2016 - 2025)

Historic EBITDA for Anika Therapeutics (ANIK) over the last 16 years, with Q3 2025 value amounting to -$2.5 million.

  • Anika Therapeutics' EBITDA rose 9139.47% to -$2.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$32.3 million, marking a year-over-year increase of 6660.87%. This contributed to the annual value of -$57.2 million for FY2024, which is 3035.53% up from last year.
  • Latest data reveals that Anika Therapeutics reported EBITDA of -$2.5 million as of Q3 2025, which was up 9139.47% from -$2.6 million recorded in Q2 2025.
  • Over the past 5 years, Anika Therapeutics' EBITDA peaked at $6.7 million during Q2 2021, and registered a low of -$62.4 million during Q4 2023.
  • Moreover, its 5-year median value for EBITDA was -$3.9 million (2022), whereas its average is -$8.5 million.
  • Per our database at Business Quant, Anika Therapeutics' EBITDA skyrocketed by 18974.53% in 2021 and then crashed by 151855.22% in 2023.
  • Quarter analysis of 5 years shows Anika Therapeutics' EBITDA stood at -$6.2 million in 2021, then skyrocketed by 37.76% to -$3.9 million in 2022, then tumbled by 1518.55% to -$62.4 million in 2023, then surged by 63.21% to -$22.9 million in 2024, then soared by 89.05% to -$2.5 million in 2025.
  • Its EBITDA stands at -$2.5 million for Q3 2025, versus -$2.6 million for Q2 2025 and -$4.2 million for Q1 2025.